FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China February 10, 2022 Auto Bot Clinical Trials, Eli Lilly and Company, Food and Drug Administration, Immunotherapy, lung cancer, New England Journal of Medicine, Prices (Fares, Fees and Rates), your-feed-healthcare 0 The panel debated whether overseas trials could be applied to a more diverse U.S. population. The decision may affect other Chinese drug trials, and spotlights the high cost of immunotherapy.